The functional gastrointestinal disorders are common disorders that are associated with significant quality-of-life impairment and considerable economic burden on the healthcare system. They are frequently associated with a comorbid psychiatric condition; this, together with a striking lack of effective pharmacological therapies, means they represent a considerable therapeutic challenge to the treating physician. In this overview, we examine the evidence to support the use of agents currently used in the management of the more common functional gastrointestinal disorders and review emerging therapies.
AkamizuT.IwakuraH.AriyasuH.HosodaH.MurayamaT.YokodeM. (2008) Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol158: 491–498.
2.
AkehurstR.L.BrazierJ.E.MathersN.O'KeefeC.KaltenthalerE.MorganA. (2002) Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics20: 455–462.
3.
AmbizasE.M.GinzburgR. (2007) Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother41: 957–964.
4.
AndresenV.CamilleriM.BusciglioI.A.GrudellA.BurtonD.McKinzieS. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology133: 761–768.
5.
ArffmannS.AndersenJ.R.HegnhojJ.Schaffalitzky de MuckadellO.B.MogensenN.B.KragE. (1985) The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. Scand J Gastroenterol20: 295–298.
6.
AtkinsonW.SheldonT.A.ShaathN.WhorwellP.J. (2004) Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut53: 1459–1464.
7.
AzizQ.ThompsonD.G.NgV.W.HamdyS.SarkarS.BrammerM.J. (2000) Cortical processing of human somatic and visceral sensation. J Neurosci20: 2657–2663.
8.
BarbaraG.StanghelliniV.CremonC.De GiorgioR.FronzoniL.SerraM. (2009) Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis27(Suppl. 1): 115–121.
9.
BarberaR.FeinleC.ReadN.W. (1995) Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol7: 1051–1057.
10.
BrandtL.J.CheyW.D.Foxx-OrensteinA.E.SchillerL.R.SchoenfeldP.S.SpiegelB.M. (2009) An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol104(Suppl. 1): S1–S35.
11.
BrennerD.M.MoellerM.J.CheyW.D.SchoenfeldP.S. (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol104: 1033–1049; quiz 1050.
12.
CamilleriM. (2010) Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther31: 35–46.
13.
ChialH.J.CamilleriM.BurtonD.ThomfordeG.OldenK.W.StephensD. (2003) Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol284: G130–G137.
14.
CiprianiA.BrambillaP.FurukawaT.GeddesJ.GregisM.HotopfM. (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev4; CD004185.
15.
CiprianiA.FurukawaT.A.SalantiG.GeddesJ.R.HigginsJ.P.ChurchillR. (2009a) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet373: 746–758.
16.
CiprianiA.SantilliC.FurukawaT.A.SignorettiA.NakagawaA.McGuireH. (2009b) Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev2; CD006532.
17.
CodlingC.O'MahonyL.ShanahanF.QuigleyE.M.MarchesiJ.R. (2010) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci55: 392–397.
18.
DaineseR.GallianiE.A.De LazzariF.Di LeoV.NaccaratoR. (1999) Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol94: 1892–1897.
19.
DeanB.B.GanoA.D.JrKnightK.OfmanJ.J.FassR. (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol2: 656–664.
20.
DinanT.G.ClarkeG.QuigleyE.M.ScottL.V.ShanahanF.CryanJ. (2008) Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol103: 2570–2576.
21.
DolinB.J. (2009) Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol31: 655–659.
22.
DrossmanD.A. (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology130: 1377–1390.
23.
DrossmanD.A.CheyW.D.JohansonJ.F.FassR.ScottC.PanasR. (2009) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther29: 329–341.
24.
DrossmanD.A.CreedF.H.OldenK.W.SvedlundJ.TonerB.B.WhiteheadW.E. (1999) Psychosocial aspects of the functional gastrointestinal disorders. Gut45(Suppl. 2): II25– II30.
25.
DrossmanD.A.LiZ.AndruzziE.TempleR.D.TalleyN.J.ThompsonW.G. (1993) U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci38: 1569–1580.
26.
FassR.SifrimD. (2009) Management of heartburn not responding to proton pump inhibitors. Gut58: 295–309.
27.
FeinleC.MeierO.OttoB.D'AmatoM.FriedM. (2001) Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut48: 347–355.
28.
FordA.C.BrandtL.J.YoungC.CheyW.D.Foxx-OrensteinA.E.MoayyediP. (2009a) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol104: 1831–1843; quiz 1844.
29.
FordA.C.SpiegelB.M.TalleyN.J.MoayyediP. (2009b) Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol7: 1279–1286.
30.
FordA.C.TalleyN.J.SchoenfeldP.S.QuigleyE.M.MoayyediP. (2009c) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut58: 367–378.
31.
FordA.C.TalleyN.J.SpiegelB.M.Foxx-OrensteinA.E.SchillerL.QuigleyE.M. (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ337; a2313.
32.
GershonM.D.TackJ. (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology132: 397–414.
33.
GorardD.A.LibbyG.W.FarthingM.J. (1994) Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther8: 159–166.
34.
GrigoleitH.G.GrigoleitP. (2005) Peppermint oil in irritable bowel syndrome. Phytomedicine12: 601–606.
35.
GweeK.A.CollinsS.M.ReadN.W.RajnakovaA.DengY.GrahamJ.C. (2003) Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut52: 523–526.
36.
HillsJ.M.AaronsonP.I. (1991) The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology101: 55–65.
37.
HiyamaT.YoshiharaM.MatsuoK.KusunokiH.KamadaT.ItoM. (2007) Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol22: 304–310.
38.
HojoM.MiwaH.YokoyamaT.OhkusaT.NagaharaA.KawabeM. (2005) Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol40: 1036–1042.
39.
JohansonJ.F.DrossmanD.A.PanasR.WahleA.UenoR. (2008a) Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther27: 685–696.
40.
JohansonJ.F.MortonD.GeenenJ.UenoR. (2008b) Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol103: 170–177.
41.
KaramanolisG.VanuytselT.SifrimD.BisschopsR.ArtsJ.CaenepeelP. (2008) Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci53: 2387–2393.
42.
KhoshooV.ArmsteadC.LandryL. (2006) Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther23: 191–196.
43.
KimD.Y.CamilleriM. (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol95: 2698–2709.
44.
Knill-JonesR.P. (1991) Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl182: 17–24.
45.
KoekG.H.SifrimD.LerutT.JanssensJ.TackJ. (2003) Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut52: 1397–1402.
46.
KoloskiN.A.TalleyN.J.BoyceP.M. (2000) The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol95: 67–71.
47.
LeeK.J.ChaD.Y.CheonS.J.YeoM.ChoS.W. (2009) Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion80: 58–63.
48.
LehmannA.JensenJ.M.BoeckxstaensG.E. (2010) GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol58: 287–313.
49.
LiebregtsT.AdamB.BredackC.RothA.HeinzelS.LesterS. (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology132: 913–920.
50.
LieverseR.J.JansenJ.B.LamersC.B. (1993) Cholecystokinin and satiation. Neth J Med42: 146–152.
51.
LockeG.R.IIILinS.C.TalleyN.J. (2005) Psychiatric disease and functional GI disorders in the community: more evidence for a casual link?Am J Gastroenterol100: 248–249.
52.
LongstrethG.F.DrossmanD.A. (2005) Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol3: 397–400.
53.
LongstrethG.F.WilsonA.KnightK.WongJ.ChiouC.F.BarghoutV. (2003) Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol98: 600–607.
54.
MalinenE.RinttilaT.KajanderK.MattoJ.KassinenA.KrogiusL. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol100: 373–382.
55.
MatsuedaK.HarasawaS.HongoM.HiwatashiN.SasakiD. (2008a) A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion77: 225–235.
56.
MatsuedaK.HarasawaS.HongoM.HiwatashiN.SasakiD. (2008b) A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol43: 1202–1211.
57.
Maxion-BergemannS.ThieleckeF.AbelF.BergemannR. (2006) Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics24: 21–37.
58.
McKeeD.P.QuigleyE.M. (1993) Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci38: 1773–1782.
59.
McQuayH.J.TramerM.NyeB.A.CarrollD.WiffenP.J.MooreR.A. (1996) A systematic review of antidepressants in neuropathic pain. Pain68: 217–227.
60.
MoayyediP.FordA.C.TalleyN.J.CremoniniF.Foxx-OrensteinA.E.BrandtL.J. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut59: 325–332.
ModlinI.M.HuntR.H.MalfertheinerP.MoayyediP.QuigleyE.M.TytgatG.N. (2009) Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group. Digestion80: 74–88.
63.
MoranT.H.DaileyM.J. (2009) Minireview: Gut peptides: targets for antiobesity drug development?Endocrinology150: 2526–2530.
64.
MorcosA.DinanT.QuigleyE.M. (2009) Irritable bowel syndrome: role of food in pathogenesis and management. J Dig Dis10: 237–246.
65.
MurrayC.D.MartinN.M.PattersonM.TaylorS.A.GhateiM.A.KammM.A. (2005) Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut54: 1693–1698.
66.
NayakA.K.KarnadD.R.AbrahamP.MistryF.P. (1997) Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called ‘chronic amebiasis'. Indian J Gastroenterol16: 137–139.
67.
NobaekS.JohanssonM.L.MolinG.AhrneS.JeppssonB. (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol95: 1231–1238.
68.
NojkovB.RubensteinJ.H.AdlisS.A.ShawM.J.SaadR.RaiJ. (2008) The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther27: 473–482.
69.
O'MahonyL.McCarthyJ.KellyP.HurleyG.LuoF.ChenK. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology128: 541–551.
70.
OhmanL.IsakssonS.LindmarkA.C.PosserudI.StotzerP.O.StridH. (2009) T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol104: 1205–1212.
71.
PaeC.U.MasandP.S.AjwaniN.LeeC.PatkarA.A. (2007) Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract61: 1708–1718.
72.
ParkM.I.CamilleriM. (2006) Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil18: 595–607.
73.
PilichiewiczA.N.FeltrinK.L.HorowitzM.HoltmannG.WishartJ.M.JonesK.L. (2008) Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol103: 2613–2623.
74.
PimentelM. (2009) Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs18: 349–358.
75.
PimentelM.ChatterjeeS.ChowE.J.ParkS.KongY. (2006a) Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci51: 1297–1301.
76.
PimentelM.KongY.ParkS. (2003) Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol98: 2700–2704.
77.
PimentelM.ParkS.MirochaJ.KaneS.V.KongY. (2006b) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med145: 557–563.
78.
QuigleyE.M. (2007) Probiotics in irritable bowel syndrome: an immunomodulatory strategy?J Am Coll Nutr26: 684S–690S.
QuigleyE.M.BytzerP.JonesR.MearinF. (2006) Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis38: 717–723.
81.
RagnarssonG.BodemarG. (1998) Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol10: 415–421.
82.
RonkainenJ.AroP.StorskrubbT.JohanssonS.E.LindT.Bolling-SternevaldE. (2005) High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol40: 275–285.
83.
SaitoY.A.SchoenfeldP.LockeG.R.III (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol97: 1910–1915.
84.
SarnelliG.JanssensJ.TackJ. (2001) Effect of intranasal sumatriptan on gastric tone and sensitivity to distension. Dig Dis Sci46: 1591–1595.
85.
SavarinoE.PohlD.ZentilinP.DulbeccoP.SammitoG.SconfienzaL. (2009) Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut58: 1185–1191.
86.
ShararaA.I.AounE.Abdul-BakiH.MounzerR.SidaniS.ElhajjI. (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol101: 326–333.
SifrimD. (2004) Acid, weakly acidic and non-acid gastro-oesophageal reflux: differences, prevalence and clinical relevance. Eur J Gastroenterol Hepatol16: 823–830.
89.
SilkD.B.DavisA.VulevicJ.TzortzisG.GibsonG.R. (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther29: 508–518.
90.
SimrenM.ManssonA.LangkildeA.M.SvedlundJ.AbrahamssonH.BengtssonU. (2001) Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion63: 108–115.
91.
SnookJ.ShepherdH.A. (1994) Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther8: 511–514.
TackJ.BisschopsR.SarnelliG. (2004) Pathophysiology and treatment of functional dyspepsia. Gastroenterology1274: 1239–1255.
94.
TackJ.CoulieB.WilmerA.AndrioliA.JanssensJ. (2000) Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut46: 468–473.
95.
TackJ.DepoortereI.BisschopsR.VerbekeK.JanssensJ.PeetersT. (2005) Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther22: 847–853.
96.
TackJ.PiessevauxH.CoulieB.CaenepeelP.JanssensJ. (1998) Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology115: 1346–1352.
97.
TackJ.Van Den ElzenB.TytgatG.WajsE.Van NuetenL.De RidderF. (2009) A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil21: 619–626; e623–e614.
98.
TakahashiM.IwamotoK.KawamuraY.NakamuraY.IshiharaR.UchiyamaY. (2010) The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol25: 260–267.
99.
TalleyN.J.ChoungR.S. (2009) Whither dyspepsia? A historical perspective of functional dyspepsia, and concepts of pathogenesis and therapy in 2009. J Gastroenterol Hepatol24(Suppl. 3): S20–S28.
100.
TalleyN.J.VakilN. (2005) Guidelines for the management of dyspepsia. Am J Gastroenterol100: 2324–2337.
101.
ThompsonW.G.IrvineE.J.PareP.FerrazziS.RanceL. (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci47: 225–235.
102.
ToniniM.PaceF. (2006) Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis24: 59–69.
103.
TrimbleK.C.FaroukR.PrydeA.DouglasS.HeadingR.C. (1995) Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci40(8): 1607–1613.
104.
TsoukaliE.SifrimD. (2010) The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?J Neurogastroenterol Motil16(3): 258–264.
105.
UenoH.ShiiyaT.NakazatoM. (2010) Translational research of ghrelin. Ann N Y Acad Sci1200: 120–127.
106.
VakilN.LaineL.TalleyN.J.ZakkoS.F.TackJ.CheyW.D. (2008) Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol103: 1906–1919.
107.
WangA.LiaoX.XiongL.PengS.XiaoY.LiuS. (2008) The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol8: 43–43.
108.
YangJ.LeeH.R.LowK.ChatterjeeS.PimentelM. (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci53: 169–174.
109.
ZijdenbosI.L.de WitN.J.van der HeijdenG.J.RubinG.QuarteroA.O. (2009) Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev1; CD006442.
110.
ZwetchkenbaumJ.BurakoffR. (1988) The irritable bowel syndrome and food hypersensitivity. Ann Allergy61: 47–49.
